The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 27, No. 9, pp. 1060-1061.
© 1993 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kovacs, M.
Right arrow Articles by Chin-Yee, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kovacs, M.
Right arrow Articles by Chin-Yee, I.

Research Articles

Thrombotic thrombocytopenic purpura associated with ticlopidine

MJ Kovacs, PY Soong, and IH Chin-Yee

OBJECTIVE: To report a case of possible ticlopidine-induced thrombotic thrombocytopenic purpura (TTP). CASE SUMMARY: A 68-year-old man was started on ticlopidine therapy for transient ischemic attack because of aspirin intolerance. Three weeks after starting therapy, the patient developed TTP, manifest by severe thrombocytopenia, renal failure, microangiopathic hemolytic anemia, and neurologic symptoms. The condition reversed over three to five days coincident with the discontinuation of ticlopidine and therapy with daily plasma infusion and exchange. No evidence of relapse was found at one-year follow-up. DISCUSSION: TTP is a well-defined clinical entity with varied etiologies. Ticlopidine has been reported as causing neutropenia and isolated thrombocytopenia. Case reports have linked ticlopidine to the development of TTP. CONCLUSIONS: Including this case there are now seven patients who have been documented as developing TTP while receiving ticlopidine. In addition to monitoring for neutropenia and isolated thrombocytopenia, patients receiving ticlopidine also should be monitored for the development of TTP.


This article has been cited by other articles:


Home page
 CMAJHome page
F. L. Paradiso-Hardy, C. M. Angelo, K. L. Lanctot, and E. A. Cohen
Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality
Can. Med. Assoc. J., November 1, 2000; 163(11): 1441 - 1448.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
B. Moy, J. C. Wang, G. D. Raffel, and J. P. Marcoux II
Hemolytic Uremic Syndrome Associated With Clopidogrel: A Case Report
Arch Intern Med, May 8, 2000; 160(9): 1370 - 1372.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
S. R. Steinhubl, W. A. Tan, J. M. Foody, E. J. Topol, and for the EPISTENT Investigators
Incidence and Clinical Course of Thrombotic Thrombocytopenic Purpura Due to Ticlopidine Following Coronary Stenting
JAMA, March 3, 1999; 281(9): 806 - 810.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
D. K. Chen, J. S. Kim, and D. M. C. Sutton
Thrombotic Thrombocytopenic Purpura Associated With Ticlopidine Use: A Report of 3 Cases and Review of the Literature
Arch Intern Med, February 8, 1999; 159(3): 311 - 314.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
Y. Kupfer and S. Tessler
Ticlopidine and Thrombotic Thrombocytopenic Purpura
N. Engl. J. Med., October 23, 1997; 337(17): 1245 - 1245.
[Full Text]

Home page
 CLIN APPL THROMB HEMOSTHome page
W. H. Wehrmacher, H. L. Messmore, R. L. Bick, and J. Fareed
Ticlopidine and Clopidogrel: Do They Have Direct Vascular Effects?
Clinical and Applied Thrombosis/Hemostasis, October 1, 1997; 3(4): 225 - 225.
[PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1993 by Harvey Whitney Books Company.